ATNM News and Press, Actinium Pharmaceuticals Inc. From 04/28/23

Actinium Highlights Successful Administration of Targeted Radiotherapy Iomab-B Across Various BMT Centers with Ease and Without Increasing Radiation Exposure Risks to Treating Nursing Staff in the Pivotal Phase 3 SIERRA Trial at the 48th Annual Oncology Nursing Society (ONS) Congress PR...

Actinium Announces Positive Pivotal Phase 3 SIERRA Trial Results of Iomab-B Showcased to the European Transplant Community in Oral Presentation at the European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting PR Newswire - EBMT oral presentation builds awaren...

Actinium Highlights First-In-Class HER3 Targeted Radiotherapy Data Demonstrating Potent Anti-Cancer Activity of in Ovarian and Colorectal Cancer Models at the AACR Annual Meeting PR Newswire -  Highly significant (p<0.0001) reduction in tumor volume in ovarian cancer mod...

Actinium Presents Data Demonstrating Actimab-A's Potential Use Against Solid Tumors by Selectively Depleting Immunosuppressive MDSCs, a Key Component of the Tumor Microenvironment, at the AACR Annual Meeting PR Newswire - Actimab-A displayed robust MDSC depletion at statisticall...

2023-04-10 08:00:00 ET Summary ATNM has finally delivered complete data from SIERRA, and it is solid. They are going to file later this year. The stock is down 50% from its catalytic highs, creating a highly derisked opportunity. I covered Actinium ( ATNM ) i...

2023-04-03 07:04:50 ET Actinium Pharmaceuticals press release ( NYSE: ATNM ): FY net loss of $33M. The Company reported cash and cash equivalents of $108.9 million as of December 31, 2022, which is projected to fund operations through 2025 For further details see: ...

Actinium Pharmaceuticals Reports 2022 Financial Results and Highlights Recent and Upcoming Clinical Data and Milestones PR Newswire -  Announced positive results from the pivotal Phase 3 SIERRA trial of Iomab-B in r/r AML patients ages 55+; achieved primary endpoint of dCR ...

Actinium to Showcase First-In-Class Targeted Radiotherapies in Two Presentations at the 2023 AACR Annual Meeting PR Newswire -  First ever data demonstrating the novel application of Actimab-A to enhance antitumor immune activity by depleting MDSCs, a population of highly i...

Actinium Pharmaceuticals Announces Dr. Sergio Giralt to Discuss Positive Results from the Pivotal Phase 3 SIERRA Trial of Iomab-B via KOL Webinar PR Newswire - KOL webinar on Tuesday, February 28, 2023 , at 8 a.m. EST - Actinium intends to file a BLA for Iomab-...

Palm Beach, FL – February 22, 2023 – FinancialNewsMedia.com News Commentary – Acute myeloid leukemia (AML) is the second most common type of leukemia diagnosed in adults and children. Leukemia is a type of cancer that mainly occurs in white blood cells. White bloo...